Aplastic Anaemia

• EMA approval · 2026-02-26
  EMA Authorised: Revolade (eltrombopag) — Novartis Europharm Limited

  The EMA authorized Revolade (eltrombopag). It covers idiopathic thrombocytopenic purpura and aplastic anaemia.

• CLINICAL_TRIALS research · 2026-01-13
  Clinical Trial Update: HID-HSCT Versus IST as First-line Treatment for SAA [NA]

  This clinical trial compares haploidentical hematopoietic stem cell transplantation (HID-HSCT) versus immunosuppressive therapy as first-lin…